Meeting
2017 ASCO Annual Meeting
Evaluation of RAD1901, a novel investigational, selective estrogen receptor degrader (SERD), for the treatment of ER-positive (ER+) advanced breast cancer.
Authors
Aditya Bardia
Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA
Aditya Bardia , Peter Kabos , Richard Elledge , Dannie Wang , Jinshan Shen , Fiona Garner , Alison O'Neill , Virginia G. Kaklamani
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT02338349
Citation
J Clin Oncol 35, 2017 (suppl; abstr 1014)
DOI
10.1200/JCO.2017.35.15_suppl.1014
Abstract #
1014
Poster Bd #
6
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
A Phase 1 study of RAD1901, an oral selective estrogen receptor degrader, in ER positive, HER2 negative, advanced breast cancer patients.
First Author: Elisabeth De Vries
Poster
2022 ASCO Annual Meeting
ARV-471, an estrogen receptor (ER) PROTAC degrader, combined with palbociclib in advanced ER+/human epidermal growth factor receptor 2–negative (HER2-) breast cancer: Phase 1b cohort (part C) of a phase 1/2 study.
First Author: Erika P. Hamilton
Poster
2020 ASCO Virtual Scientific Program
A phase I dose escalation and expansion study of the next generation oral SERD AZD9833 in women with ER-positive, HER2-negative advanced breast cancer.
First Author: Erika Paige Hamilton
Poster
2020 ASCO Virtual Scientific Program
A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer.
First Author: Elgene Lim